Evidence map›Paper›PMID 36002841›Full record

Trial reportBMC medicine2022

Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children.

Gaoqian Feng, Liriye Kurtovic, Paul A Agius, Elizabeth H Aitken, Jahit Sacarlal, Bruce D Wines, P Mark Hogarth, Stephen J Rogerson, Freya J I Fowkes, Carlota Dobaño and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
In one paragraph

Trial report in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00197041 (A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule in Toddlers and Children Aged 1 to 4 Years in a Malaria-endemic Region of Mozambique.), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00197041 phase2completednot on this map

A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule in Toddlers and Children Aged 1 to 4 Years in a Malaria-endemic Region of Mozambique.

TypeinterventionalSponsorGlaxoSmithKlineRan2003 to 2005Enrolled2,022ConditionsMalariaArmsRTS,S/AS02A
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Overview of the host immune response toJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Iron, Hepcidin, and Immunity.Advances in experimental medicine and biology · 2025
    Review
  12. Article
  13. Malaria vaccines: a new era of prevention and control.Nature reviews. Microbiology · 2024
    Review
  14. Article
  15. Precision adjuvants for pediatric vaccines.Science translational medicine · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Malaria Vaccines: Progress to Date.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Gaoqian FengBurnet Institute, Melbourne, Australia.
Liriye Kurtovic *Burnet Institute, Melbourne, Australia.
Paul A Agius *Burnet Institute, Melbourne, Australia.
Elizabeth H AitkenPeter Doherty Institute, The University of Melbourne, Melbourne, Australia.
Jahit SacarlalCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Bruce D WinesBurnet Institute, Melbourne, Australia.
P Mark HogarthBurnet Institute, Melbourne, Australia.
Stephen J RogersonDepartment of Medicine, The University of Melbourne, Melbourne, Australia.
Freya J I FowkesBurnet Institute, Melbourne, Australia.
Carlota DobañoCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
James G BeesonBurnet Institute, Melbourne, Australia. beeson@burnet.edu.au.
Monash University · AUUniversity of Melbourne · AUBurnet Institute · AUBarcelona Institute for Global Health · ESManhiça Health Research Centre · MZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRTS,S is the first malaria vaccine recommended for implementation among young children at risk. However, vaccine efficacy is modest and short-lived. Antibodies play the major role in vaccine-induced immunity, but knowledge on the induction, decay, and determinants of antibody function is limited, especially among children. Antibodies that promote opsonic phagocytosis and other cellular functions appear to be important contributors to RTS,S immunity.

methodsWe studied a phase IIb trial of RTS,S/AS02 conducted in young children in malaria-endemic regions of Mozambique. We evaluated the induction of antibodies targeting the circumsporozoite protein (CSP, vaccine antigen) that interact with Fcγ-receptors (FcRγs) and promote phagocytosis (neutrophils, monocytes, THP-1 cells), antibody-dependent respiratory burst (ADRB) by neutrophils, and natural killer (NK) cell activity, as well as the temporal kinetics of responses over 5 years of follow-up (ClinicalTrials.gov registry number NCT00197041).

resultsRTS,S vaccination induced CSP-specific IgG with FcγRIIa and FcγRIII binding activity and promoted phagocytosis by neutrophils, THP-1 monocytes, and primary human monocytes, neutrophil ADRB activity, and NK cell activation. Responses were highly heterogenous among children, and the magnitude of neutrophil phagocytosis by antibodies was relatively modest, which may reflect modest vaccine efficacy. Induction of functional antibodies was lower among children with higher malaria exposure. Functional antibody magnitude and the functional activity of antibodies largely declined within a year post-vaccination, and decay were highest in the first 6 months, consistent with the decline in vaccine efficacy over that time. Decay rates varied for different antibody parameters and decay was slower for neutrophil phagocytosis. Biostatistical modelling suggested IgG1 and IgG3 contribute in promoting FcγR binding and phagocytosis, and IgG targeting the NANP-repeat and C-terminal regions CSP were similarly important for functional activities.

conclusionsResults provide new insights to understand the modest and time-limited efficacy of RTS,S in children and the induction of antibody functional activities. Improving the induction and maintenance of antibodies that promote phagocytosis and cellular functions, and combating the negative effect of malaria exposure on vaccine responses are potential strategies for improving RTS,S efficacy and longevity.

Indexed as

MalariaMalaria, FalciparumMalaria VaccinesAntibodies, ProtozoanChildChild, PreschoolHumansImmunoglobulin GPlasmodium falciparumProtozoan ProteinsVaccinationAntibodies, ProtozoanImmunoglobulin GMalaria VaccinesProtozoan ProteinsRTS malaria vaccineAntibodiesChildrenFcγ-receptorMalariaMonocytesNeutrophilsPhagocytosisVaccines

Identifiers

PMID36002841
PMCPMC9402280
OpenAlexW4293103260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.